Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Brexogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Brexogen, BMI Korea Form Exosome Therapy Tech Transfer Deal
Details : Under the icensing agreement, BMI Korea has secured the exclusive rights of BxC-I17e, an innovative exosome-based injectable therapeutics for the treatment of Atopic Dermatitis.
Product Name : BxC-I17e
Product Type : Other Large Molecule
Upfront Cash : $2.3 million
February 19, 2025
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Brexogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
